Literature DB >> 32135017

A bispecific approach to improving CAR T cells in AML.

Naval Daver1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32135017     DOI： 10.1182/blood.2020004791

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  5 in total

1.  An Update on Immune Based Therapies in Acute Myeloid Leukemia: 2021 and Beyond!

Authors:  Fadi Haddad; Naval Daver
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 2.  Extending the Promise of Chimeric Antigen Receptor T-Cell Therapy Beyond Targeting CD19+ Tumors.

Authors:  Natalie S Grover; Nicholas Tschernia; Gianpietro Dotti; Barbara Savoldo
Journal:  J Clin Oncol       Date:  2021-01-12       Impact factor: 44.544

Review 3.  Hematopoeitic Cell Transplantation and CAR T-Cell Therapy: Complements or Competitors?

Authors:  Scott R Goldsmith; Armin Ghobadi; John F DiPersio
Journal:  Front Oncol       Date:  2020-12-22       Impact factor: 6.244

Review 4.  Chimeric Antigen Receptor-Engineered Natural Killer (CAR NK) Cells in Cancer Treatment; Recent Advances and Future Prospects.

Authors:  Reza Elahi; Amir Hossein Heidary; Kaveh Hadiloo; Abdolreza Esmaeilzadeh
Journal:  Stem Cell Rev Rep       Date:  2021-09-02       Impact factor: 6.692

Review 5.  Acute Myeloid Leukemia Mutations and Future Mechanistic Target to Overcome Resistance.

Authors:  Rehan Uddin; Noureldian H E Darwish; Shaker A Mousa
Journal:  Curr Treat Options Oncol       Date:  2021-07-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.